Table 1—

Baseline characteristics of the total study population

CharacteristicsTotal population
n60
Age (years)65.2 ± 10
Sex (male)44 (73.3)
Type 1 diabetes7 (11.6)
Type 2 diabetes53 (88.4)
Diagnosis of diabetes (months)79.5 ± 64.1
Fasting insulin (pmol/l)36.3 ± 12.3
Preprocedural A1C (%)7.6 ± 1.8
Preprocedural glycemia (mg/dl)164 ± 74.5
Hypertension49 (81.6)
Current smoker12 (20)
Family history of CAD22 (36.6)
Total cholesterol (mg/ml)179.5 ± 45.7
Triglycerides (mg/dl)155 ± 103.2
Chronic renal insufficiency*13 (21.6)
Previous MI26 (43.3)
Previous CABG2 (0.3)
Previous PCI3 (0.5)
ACS32 (53.3)
Troponin I (ng/ml)0.4 ± 1.8
Creatine kinase–MB isoenzyme (ng/ml)155 ± 5.4
CRP (mg/dl)0.9 ± 1.2
Multivessel disease55 (91.6)
Ejection fraction (%)54.5 ± 8.6
Sulphonil ureas21 (35)
Biguanide25 (41.6)
Other antidiabetes drugs8 (13.3)
Statins48 (80)
ACE inhibitors or ARBs50 (83.3)
Aspirin53 (88.3)
Thienopyridine-derived agents48 (80)
Glycoprotein IIb/IIIa8 (13.3)
Calcium channel blockers21 (35)
β-blockers36 (60)
  • Data are means ± SD or n (%). ARB, angiotensin receptor blocker; ACS, acute coronary syndrome; CAD, coronary artery disease; CABG, coronary artery bypass grafing; CRP, C-reactive protein; MI, myocardial infarction.

  • * Defined as a serum creatinine level ≥1.5 mg/dl (≥132 μmol/l).